Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy
A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alo...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 1976-04, Vol.17 (4), p.436-440 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 4 |
| container_start_page | 436 |
| container_title | International journal of cancer |
| container_volume | 17 |
| creator | Olweny, Charles L. M. Katongole‐Mbidde, Edward Kaddu‐Mukasa, Albert Atine, Isaac Owor, Raphael Lwanga, Stephen Carswell, W. Magrath, Ian T. |
| description | A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX‐ and COM‐treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same. |
| doi_str_mv | 10.1002/ijc.2910170404 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ijc_2910170404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IJC2910170404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3394-7d2f2a956e2c58ebfe79cefd372a9fe1d991233831f0c540c48d9d78856a4e0b3</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi3ErRRWJoZsTCnHiRPHbFBxKUJCQmWOHOe4dclNdgoKE4_AM_IkpAoCNpZzpPOf_xs-Qo4pTChAcGZWahIICpQDA7ZFRhQE9yGg0TYZ9Q_gcxrG--TAuRUApRGwPbLLeZwwGJFiblG2JVatV2vvcm2fTdueOq_oymZZl_Lce5RVXpfmDXNPFaYyShZea00_-4Iz1aLAz_cPudggXtC6tfNUXWamkq2pK08tsazbJVrZdIdkR8vC4dH3HpOn66v59Na_f7iZTS_ufRWGgvk8D3QgRRRjoKIEM41cKNR5yPurRpoLQYMwTEKqQUUMFEtykfMkiWLJELJwTCYDV9naOYs6bawppe1SCulGWtpLS3-l9YWTodCssxLzn_fBUh-LIX41BXb_wNLZ3fQP-gsmtnuP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Olweny, Charles L. M. ; Katongole‐Mbidde, Edward ; Kaddu‐Mukasa, Albert ; Atine, Isaac ; Owor, Raphael ; Lwanga, Stephen ; Carswell, W. ; Magrath, Ian T.</creator><creatorcontrib>Olweny, Charles L. M. ; Katongole‐Mbidde, Edward ; Kaddu‐Mukasa, Albert ; Atine, Isaac ; Owor, Raphael ; Lwanga, Stephen ; Carswell, W. ; Magrath, Ian T.</creatorcontrib><description>A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX‐ and COM‐treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.2910170404</identifier><identifier>PMID: 776840</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Burkitt Lymphoma - drug therapy ; Burkitt Lymphoma - mortality ; Clinical Trials as Topic ; Cyclophosphamide - therapeutic use ; Drug Evaluation ; Drug Therapy, Combination ; Humans ; Methotrexate - therapeutic use ; Vincristine - therapeutic use</subject><ispartof>International journal of cancer, 1976-04, Vol.17 (4), p.436-440</ispartof><rights>Copyright © 1976 Wiley‐Liss, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3394-7d2f2a956e2c58ebfe79cefd372a9fe1d991233831f0c540c48d9d78856a4e0b3</citedby><cites>FETCH-LOGICAL-c3394-7d2f2a956e2c58ebfe79cefd372a9fe1d991233831f0c540c48d9d78856a4e0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.2910170404$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.2910170404$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/776840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olweny, Charles L. M.</creatorcontrib><creatorcontrib>Katongole‐Mbidde, Edward</creatorcontrib><creatorcontrib>Kaddu‐Mukasa, Albert</creatorcontrib><creatorcontrib>Atine, Isaac</creatorcontrib><creatorcontrib>Owor, Raphael</creatorcontrib><creatorcontrib>Lwanga, Stephen</creatorcontrib><creatorcontrib>Carswell, W.</creatorcontrib><creatorcontrib>Magrath, Ian T.</creatorcontrib><title>Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX‐ and COM‐treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.</description><subject>Burkitt Lymphoma - drug therapy</subject><subject>Burkitt Lymphoma - mortality</subject><subject>Clinical Trials as Topic</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Drug Evaluation</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Methotrexate - therapeutic use</subject><subject>Vincristine - therapeutic use</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi3ErRRWJoZsTCnHiRPHbFBxKUJCQmWOHOe4dclNdgoKE4_AM_IkpAoCNpZzpPOf_xs-Qo4pTChAcGZWahIICpQDA7ZFRhQE9yGg0TYZ9Q_gcxrG--TAuRUApRGwPbLLeZwwGJFiblG2JVatV2vvcm2fTdueOq_oymZZl_Lce5RVXpfmDXNPFaYyShZea00_-4Iz1aLAz_cPudggXtC6tfNUXWamkq2pK08tsazbJVrZdIdkR8vC4dH3HpOn66v59Na_f7iZTS_ufRWGgvk8D3QgRRRjoKIEM41cKNR5yPurRpoLQYMwTEKqQUUMFEtykfMkiWLJELJwTCYDV9naOYs6bawppe1SCulGWtpLS3-l9YWTodCssxLzn_fBUh-LIX41BXb_wNLZ3fQP-gsmtnuP</recordid><startdate>19760415</startdate><enddate>19760415</enddate><creator>Olweny, Charles L. M.</creator><creator>Katongole‐Mbidde, Edward</creator><creator>Kaddu‐Mukasa, Albert</creator><creator>Atine, Isaac</creator><creator>Owor, Raphael</creator><creator>Lwanga, Stephen</creator><creator>Carswell, W.</creator><creator>Magrath, Ian T.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19760415</creationdate><title>Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy</title><author>Olweny, Charles L. M. ; Katongole‐Mbidde, Edward ; Kaddu‐Mukasa, Albert ; Atine, Isaac ; Owor, Raphael ; Lwanga, Stephen ; Carswell, W. ; Magrath, Ian T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3394-7d2f2a956e2c58ebfe79cefd372a9fe1d991233831f0c540c48d9d78856a4e0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Burkitt Lymphoma - drug therapy</topic><topic>Burkitt Lymphoma - mortality</topic><topic>Clinical Trials as Topic</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Drug Evaluation</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Methotrexate - therapeutic use</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olweny, Charles L. M.</creatorcontrib><creatorcontrib>Katongole‐Mbidde, Edward</creatorcontrib><creatorcontrib>Kaddu‐Mukasa, Albert</creatorcontrib><creatorcontrib>Atine, Isaac</creatorcontrib><creatorcontrib>Owor, Raphael</creatorcontrib><creatorcontrib>Lwanga, Stephen</creatorcontrib><creatorcontrib>Carswell, W.</creatorcontrib><creatorcontrib>Magrath, Ian T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olweny, Charles L. M.</au><au>Katongole‐Mbidde, Edward</au><au>Kaddu‐Mukasa, Albert</au><au>Atine, Isaac</au><au>Owor, Raphael</au><au>Lwanga, Stephen</au><au>Carswell, W.</au><au>Magrath, Ian T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>1976-04-15</date><risdate>1976</risdate><volume>17</volume><issue>4</issue><spage>436</spage><epage>440</epage><pages>436-440</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX‐ and COM‐treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>776840</pmid><doi>10.1002/ijc.2910170404</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 1976-04, Vol.17 (4), p.436-440 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_ijc_2910170404 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Burkitt Lymphoma - drug therapy Burkitt Lymphoma - mortality Clinical Trials as Topic Cyclophosphamide - therapeutic use Drug Evaluation Drug Therapy, Combination Humans Methotrexate - therapeutic use Vincristine - therapeutic use |
| title | Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T13%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Burkitt's%20lymphoma:%20Randomized%20clinical%20trial%20of%20single%E2%80%90agent%20versus%20combination%20chemotherapy&rft.jtitle=International%20journal%20of%20cancer&rft.au=Olweny,%20Charles%20L.%20M.&rft.date=1976-04-15&rft.volume=17&rft.issue=4&rft.spage=436&rft.epage=440&rft.pages=436-440&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.2910170404&rft_dat=%3Cwiley_cross%3EIJC2910170404%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/776840&rfr_iscdi=true |